Semaglutide (Beijing Kangchuanglian Biopharma/Cspc)

司美格鲁肽 (北京抗创联生物/石药集团)

Report date: 2026/03/27 20:01:50

Base Information

Drug NameSemaglutide (Beijing Kangchuanglian Biopharma/Cspc)
Drug Alias Name司美格鲁肽长效注射液SYH9017SYH-9017
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsOverweightObesity
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCspc Baike (Shandong) Biopharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Kangchuanglian Biopharmaceutical Technology Research Co LtdCspc Baike (Shandong) Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsOverweightObesity
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A